British drugmaker GSK (GSK.L), opens new tab named insider Luke Miels as its CEO designate on Monday to succeed Emma Walmsley, who will step down after nine years in the role.<\/p>\n
Miels will be tasked with leading a new phase for the company and delivering GSK’s sales target of more than 40 billion pounds ($53.78 billion) by 2031.<\/p>\n
He will assume full responsibilities as CEO on January 1.<\/p>\n
REMUNERATION:
\nMiels’ starting annual base salary will be 1.38 million pounds, below Walmsley’s current salary, GSK said. Walmsley’s 2025 salary is 1.43 million pounds, according to GSK’s annual report.
\nHe will also receive an on-target yearly bonus of 150% and a long-term incentive grant 7.25 times his salary.
\nWHO IS MIELS?
\nMiels, 50, joined GSK as its chief commercial officer in 2017, managing its global medicines and vaccines portfolio, with annual sales topping 20 billion pounds across over 100 countries.
\nThe Australian national holds a biology degree from Flinders University and an MBA from Macquarie University in Australia.
\nFrom his beginnings as a sales representative at AstraZeneca, he went on to assume senior roles at global pharmaceutical giants such as Sanofi and Roche.
\nCAREER PATH:
\nAstraZeneca
\n* 1995 \u2013 2000: Held various sales and marketing roles
\nSanofi-Aventis (SASY.PA), opens new tab
\n* 2004 \u2013 2006: Vice President, Sales Metabolism, New Jersey, USA
\n* 2004: Integration Officer, North America, during the Sanofi\/Aventis merger
\n* 2003 \u2013 2004: General Manager & Managing Director, Aventis Thailand
\n* 2002 \u2013 2003: General Manager & Managing Director (Acting)
\n* 2000 \u2013 2001: Head, Strategic Planning and Portfolio Management
\nRoche Pharmaceuticals (ROG.S), opens new tab
\n* 2009 \u2013 2014: Regional Head, Asia Pacific, based first in Shanghai and then Singapore
\n* 2006 \u2013 2009: VP\/Head of Metabolism & Anemia Global Marketing, Switzerland
\nAstraZeneca (AZN.L), opens new tab
\n* May 2014 \u2013 August 2017: Executive Vice President for the European business. Prior to that, Miels served as Executive Vice President of Global Product and Portfolio Strategy, Global Medical Affairs, and Corporate Affairs
\nGSK
\n* September 2017 – Present: Chief Commercial Officer<\/p>\n","protected":false},"excerpt":{"rendered":"
British drugmaker GSK (GSK.L), opens new tab named insider Luke Miels as its CEO designate on Monday to succeed Emma Walmsley, who will step down after nine years in the role. Miels will be tasked with leading a new phase for the company and delivering GSK’s sales target of more than 40 billion pounds ($53.78 […]<\/p>\n","protected":false},"author":2,"featured_media":2032,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[591],"class_list":{"0":"post-2031","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sitefansalaran-industry-news","8":"tag-who-is-gsks-next-ceo-luke-miels"},"yoast_head":"\n